IQVIA Holdings Inc. $IQV Shares Bought by Vident Advisory LLC

Key Points

• Vident Advisory LLC increased its stake in IQVIA Holdings by 60.4%, owning 4,499 shares valued at $793,000, according to its recent SEC filing.
• IQVIA reported $4.02 billion in revenue for the last quarter, exceeding estimates, with earnings per share (EPS) of $2.81, beating the consensus by $0.04.
• Wall Street analysts hold a positive outlook on IQVIA, with a consensus "Moderate Buy" rating and an average price target of $229.86.

Vident Advisory LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 60.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,499 shares of the medical research company's stock after purchasing an additional 1,694 shares during the quarter. Vident Advisory LLC's holdings in IQVIA were worth $793,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. American National Bank & Trust purchased a new position in shares of IQVIA in the 1st quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd increased its position in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA during the first quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on IQV. Barclays increased their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Truist Financial raised their price target on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Robert W. Baird upped their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Finally, JPMorgan Chase & Co. cut their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Eighteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $229.64.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Down 1.1%

Shares of IQVIA stock traded down $2.12 during trading on Wednesday, hitting $187.52. 145,323 shares of the stock traded hands, compared to its average volume of 1,906,096. The firm has a market cap of $31.88 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $248.03. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock's fifty day simple moving average is $181.03 and its 200 day simple moving average is $167.36.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the business posted $2.64 EPS. IQVIA's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.